Immunovant’s batoclimab failed to meet primary endpoints in a pair of Phase 3 trials in thyroid eye disease, according to reporting tied to Roivant disclosures. The results mark another setback for FcRn inhibition in TED after the program had already shown limited progress in related indications. In the trials, batoclimab did not achieve the targeted proptosis reduction after the high-dose and low-dose treatment phases, with Roivant indicating no new safety signals while pointing to stronger effects during the higher-dose period. The company also signaled it intends to review future plans for development with partner HanAll. The setback narrows the competitive space for TED drug development and intensifies focus on whether FcRn-based approaches can achieve clinically meaningful improvement versus other mechanisms already in late-stage evaluation. For biotech development strategy, the readout is another example of how receptor biology strength in earlier datasets can still fail to translate into endpoint-level outcomes across complex autoimmune eye disease populations.